Marken opens clinical trial logistics hub in Melbourne, Australia

The new location joins Sydney and Brisbane as the third Australian hub and solidifies the company’s position as the leader in Australia for clinical trial supply chain solutions.

The post Marken opens clinical trial logistics hub in Melbourne, Australia appeared first on Pharma Business review.

Novelion’s Myalepta gets European approval to treat generalized and partial lipodystrophy

Myalepta has been approved as an adjunct to diet, as a replacement therapy to treat the complications of leptin deficiency in lipodystrophy (LD) patients with confirmed congenital generalized

The post Novelion’s Myalepta gets European approval to treat generalized and partial lipodystrophy appeared first on Pharma Business review.

Emergent starts phase 1 trial of Zika virus immune globulin therapeutic

ZIKV-IG was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) in December 2017. Emergent BioSolutions senior vice president and antibody therapeutics business unit head

The post Emergent starts phase 1 trial of Zika virus immune globulin therapeutic appeared first on Pharma Business review.

Pfizer secures European approval for Xeljanz to treat ulcerative colitis

The marketing authorization has been granted for Xeljanz10 mg twice-daily (BID) for at least eight weeks, followed by Xeljanz 5mg BID or 10 mg BID, to treat adult

The post Pfizer secures European approval for Xeljanz to treat ulcerative colitis appeared first on Pharma Business review.

Amgen breaks ground on $200m biomanufacturing facility in US

The company expects to invest up to $200m in the approximately 120,000ft² biomanufacturing plant at its West Greenwich campus in Rhode Island. Amgen will use its next-generation biomanufacturing

The post Amgen breaks ground on $200m biomanufacturing facility in US appeared first on Pharma Business review.

Daiichi Sankyo signs licensing deal with Glycotope for Gatipotuzumab ADC

The deal combines Daiichi Sankyo’s ADC technology with Glycotope’s investigational tumor-associated TA-MUC1 antibody gatipotuzumab (formerly PankoMab-GEX), building on a previous 2017 option agreement. Under the terms of the

The post Daiichi Sankyo signs licensing deal with Glycotope for Gatipotuzumab ADC appeared first on Pharma Business review.

Marken opens customer solutions center in Russia

In addition, Marken has begun their unique hybrid service for shipments into Russia for drug storage and distribution and from Russia for biologic sample shipments.  Together, these new

The post Marken opens customer solutions center in Russia appeared first on Pharma Business review.

RedHill’s RHB-104 meets primary endpoint in phase III Crohn’s disease study

The company has announced the positive top-line safety and efficacy results from the MAP US study, which showed superiority of RHB-104 over placebo. RHB-104 is a proprietary and

The post RedHill’s RHB-104 meets primary endpoint in phase III Crohn’s disease study appeared first on Pharma Business review.

Lilly extends cancer research collaboration with Dana-Farber

Since 2015, scientists from Lilly and Dana-Farber have been working together on pre-clinical and clinical studies, molecular analyses of patient samples and the design and conduct of clinical

The post Lilly extends cancer research collaboration with Dana-Farber appeared first on Pharma Business review.

Progenics’ Azedra gets FDA approval for rare adrenal gland tumors

The approval is for the intravenous use of the Azedra injection in patients whose adrenal gland tumors are unresectable and have spread beyond the original tumor site and

The post Progenics’ Azedra gets FDA approval for rare adrenal gland tumors appeared first on Pharma Business review.